查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1386998

放射性药物治疗市场报告：2030 年趋势、预测与竞争分析

Radiopharmaceutical Theranostics Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

放射性药物治疗诊断趋势与预测

到 2030 年，全球放射性药物治疗诊断市场预计将达到 39 亿美元，2024 年至 2030 年年复合成长率为 11.2%。该市场的主要驱动因素是癌症发生率的增加和心血管疾病治疗应用的增加。全球放射性药物治疗市场的未来前景广阔，医院、诊断影像中心以及学术和研究机构市场都有机会。

放射性药物治疗诊断市场洞察

Lucintel 预测 PET 示踪剂将在预测期内达到最高成长。

由于技术先进的系统的可用性和医院数量的不断增加，医院可能仍然是该市场中最大的部分。

由于慢性病的增加、放射性药物和宠物扫描仪的容易取得，预计北美在预测期内将出现最高的成长。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2. 未来哪个细分市场成长较快？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和商业风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
  • Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球放射性药物治疗市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第3章2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球放射性药物治疗市场趋势（2018-2023）与预测（2024-2030）
  • 按产品类型分類的全球放射性药物治疗市场
    • α发射体
    • β发送器
    • PET示踪剂
  • 全球放射性药物治疗市场（按来源）
    • 核子反应炉
    • 迴旋加速器
  • 按适应症分類的全球放射性药物治疗市场
    • 肿瘤学
    • 心臟病学
    • 神经病学
    • 其他的
  • 按最终用途分類的全球放射性药物治疗市场
    • 医院
    • 影像诊断中心
    • 学术研究所
    • 其他的

第4章2018-2030年分地区市场趋势及预测分析

  • 全球放射性药物治疗市场按地区划分
  • 北美放射性药物治疗诊断市场
  • 欧洲放射性药物治疗诊断市场
  • 亚太地区放射性药物治疗诊断市场
  • 其他区域放射性药物治疗诊断市场

第5章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第6章成长机会与策略分析

  • 成长机会分析
    • 按产品类型分類的全球放射性药物治疗市场成长机会
    • 全球放射性药物治疗市场成长机会（依来源）
    • 按适应症分類的全球放射性药物治疗市场成长机会
    • 按最终用途分類的全球放射性药物治疗市场成长机会
    • 按地区分類的全球放射性药物治疗市场成长机会
  • 全球放射性药物治疗市场的新兴趋势
  • 战略分析
    • 新产品开发
    • 扩大全球放射性药物治疗市场的能力
    • 全球放射性药物治疗市场的合併、收购与合资企业
    • 认证和许可

第7章主要企业概况

  • Bayer
  • GE HealthCare Technologies
  • Curium
  • Lantheus Medical Imaging
  • Telix Pharmaceuticals
  • Cardinal Health
  • Advanced Accelerator Applications
  • Jubilant Radiopharma
  • Theragnostics
  • NuView Life Sciences
简介目录

Radiopharmaceutical Theranostics Trends and Forecast

The future of the global radiopharmaceutical theranostics market looks promising with opportunities in the hospital, diagnostic imaging center, and academic & research institute markets. The global radiopharmaceutical theranostics market is expected to reach an estimated $3.9 billion by 2030 with a CAGR of 11.2% from 2024 to 2030. The major drivers for this market are increasing incidence of cancer and rising application in treatment of cardiovascular disorders.

A more than 150-page report is developed to help in your business decisions.

Radiopharmaceutical Theranostics by Segment

The study includes a forecast for the global radiopharmaceutical theranostics by product type, source, indication, end use, and region.

Radiopharmaceutical Theranostics Market by Product Type [Shipment Analysis by Value from 2018 to 2030]:

  • Alpha Emitters
  • Beta Emitters
  • PET Tracers

Radiopharmaceutical Theranostics Market by Source [Shipment Analysis by Value from 2018 to 2030]:

  • Nuclear Reactors
  • Cyclotrons

Radiopharmaceutical Theranostics Market by Indication [Shipment Analysis by Value from 2018 to 2030]:

  • Oncology
  • Cardiology
  • Neurology
  • Others

Radiopharmaceutical Theranostics Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals
  • Diagnostic Imaging Centers
  • Academic & Research Institutes
  • Others

Radiopharmaceutical Theranostics Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Radiopharmaceutical Theranostics Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies radiopharmaceutical theranostics companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the radiopharmaceutical theranostics companies profiled in this report include-

  • Bayer
  • GE Healthcare Technologies
  • Curium
  • Lantheus Medical Imaging
  • Telix Pharmaceuticals
  • Cardinal Health
  • Advanced Accelerator Applications
  • Jubilant Radiopharma
  • Theragnostics
  • Nuview Life Sciences

Radiopharmaceutical Theranostics Market Insights

Lucintel forecasts that PET tracers is expected to witness highest growth over the forecast period.

Within this market, hospitals will remain the largest segment due to availability of technologically advanced systems and rising number of hospitals.

North America is expected to witness highest growth over the forecast period due to the growing prevalence of chronic diseases and easy availability of radiopharmaceuticals and pet scanners in the region.

Features of the Global Radiopharmaceutical Theranostics Market

Market Size Estimates: Radiopharmaceutical theranostics market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Radiopharmaceutical theranostics market size by various segments, such as by product type, source, indication, end use, and region in terms of value ($B).

Regional Analysis: Radiopharmaceutical theranostics market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product types, sources, indications, end uses, and regions for the radiopharmaceutical theranostics market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the radiopharmaceutical theranostics market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the radiopharmaceutical theranostics market size?

Answer: The global radiopharmaceutical theranostics market is expected to reach an estimated $3.9 billion by 2030.

Q.2 What is the growth forecast for radiopharmaceutical theranostics market?

Answer: The global radiopharmaceutical theranostics market is expected to grow with a CAGR of 11.2% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the radiopharmaceutical theranostics market?

Answer: The major drivers for this market are increasing incidence of cancer and rising application in treatment of cardiovascular disorders.

Q4. What are the major segments for radiopharmaceutical theranostics market?

Answer: The future of the global radiopharmaceutical theranostics market looks promising with opportunities in the hospital, diagnostic imaging center, and academic & research institute markets.

Q5. Who are the key radiopharmaceutical theranostics market companies?

Answer: Some of the key radiopharmaceutical theranostics companies are as follows:

  • Bayer
  • GE Healthcare Technologies
  • Curium
  • Lantheus Medical Imaging
  • Telix Pharmaceuticals
  • Cardinal Health
  • Advanced Accelerator Applications
  • Jubilant Radiopharma
  • Theragnostics
  • Nuview Life Sciences

Q6. Which radiopharmaceutical theranostics market segment will be the largest in future?

Answer: Lucintel forecasts that PET tracers is expected to witness highest growth over the forecast period.

Q7. In radiopharmaceutical theranostics market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to the growing prevalence of chronic diseases and easy availability of radiopharmaceuticals and pet scanners in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the radiopharmaceutical theranostics market by product type (alpha emitters, beta emitters, and PET tracers), source (nuclear reactors and cyclotrons), indication (oncology, cardiology, neurology, and others), end use (hospitals, diagnostic imaging centers, academic & research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Radiopharmaceutical Theranostics Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Radiopharmaceutical Theranostics Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Radiopharmaceutical Theranostics Market by Product Type
    • 3.3.1: Alpha Emitters
    • 3.3.2: Beta Emitters
    • 3.3.3: PET Tracers
  • 3.4: Global Radiopharmaceutical Theranostics Market by Source
    • 3.4.1: Nuclear Reactors
    • 3.4.2: Cyclotrons
  • 3.5: Global Radiopharmaceutical Theranostics Market by Indication
    • 3.5.1: Oncology
    • 3.5.2: Cardiology
    • 3.5.3: Neurology
    • 3.5.4: Others
  • 3.6: Global Radiopharmaceutical Theranostics Market by End Use
    • 3.6.1: Hospitals
    • 3.6.2: Diagnostic Imaging Centers
    • 3.6.3: Academic & Research Institutes
    • 3.6.4: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Radiopharmaceutical Theranostics Market by Region
  • 4.2: North American Radiopharmaceutical Theranostics Market
    • 4.2.2: North American Radiopharmaceutical Theranostics Market by End Use: Hospitals, Diagnostic Imaging Centers, Academic & Research Institutes, and Others
  • 4.3: European Radiopharmaceutical Theranostics Market
    • 4.3.1: European Radiopharmaceutical Theranostics Market by Product Type: Alpha Emitters, Beta Emitters, and PET Tracers
    • 4.3.2: European Radiopharmaceutical Theranostics Market by End Use: Hospitals, Diagnostic Imaging Centers, Academic & Research Institutes, and Others
  • 4.4: APAC Radiopharmaceutical Theranostics Market
    • 4.4.1: APAC Radiopharmaceutical Theranostics Market by Product Type: Alpha Emitters, Beta Emitters, and PET Tracers
    • 4.4.2: APAC Radiopharmaceutical Theranostics Market by End Use: Hospitals, Diagnostic Imaging Centers, Academic & Research Institutes, and Others
  • 4.5: ROW Radiopharmaceutical Theranostics Market
    • 4.5.1: ROW Radiopharmaceutical Theranostics Market by Product Type: Alpha Emitters, Beta Emitters, and PET Tracers
    • 4.5.2: ROW Radiopharmaceutical Theranostics Market by End Use: Hospitals, Diagnostic Imaging Centers, Academic & Research Institutes, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Radiopharmaceutical Theranostics Market by Product Type
    • 6.1.2: Growth Opportunities for the Global Radiopharmaceutical Theranostics Market by Source
    • 6.1.3: Growth Opportunities for the Global Radiopharmaceutical Theranostics Market by Indication
    • 6.1.4: Growth Opportunities for the Global Radiopharmaceutical Theranostics Market by End Use
    • 6.1.5: Growth Opportunities for the Global Radiopharmaceutical Theranostics Market by Region
  • 6.2: Emerging Trends in the Global Radiopharmaceutical Theranostics Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Radiopharmaceutical Theranostics Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Radiopharmaceutical Theranostics Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Bayer
  • 7.2: GE HealthCare Technologies
  • 7.3: Curium
  • 7.4: Lantheus Medical Imaging
  • 7.5: Telix Pharmaceuticals
  • 7.6: Cardinal Health
  • 7.7: Advanced Accelerator Applications
  • 7.8: Jubilant Radiopharma
  • 7.9: Theragnostics
  • 7.10: NuView Life Sciences